Inhibition by islet-activating protein, pertussis toxin, of P2-purinergic receptor-mediated iodide efflux and phosphoinositide turnover in FRTL-5 cells.
Exposure of FRTL-5 thyroid cells to ATP (1 microM to 1 mM) resulted in the stimulation of I- efflux in association with the induction of inositol trisphosphate production and intracellular Ca2+ mobilization. Nonhydrolyzable ATP derivatives, ADP and GTP, were also as effective in magnitude as ATP, whereas neither AMP nor adenosine exerted significant effect on I- efflux, suggesting a P2-purinergic receptor-mediated activation of I- efflux. Treatment of the cells with the islet-activating protein (IAP) pertussis toxin, which ADP-ribosylated a 41,000 mol wt membrane protein, effectively suppressed the phosphoinositide response to ATP in addition to ATP-dependent I- efflux at agonist concentrations below 10 microM. In contrast, the I- efflux stimulated by TSH, A23187, or phorbol myristate acetate was insusceptible to IAP. The IAP substrate, probably GTP-binding protein, is hence proposed to mediate the activation of P2-purinergic receptor-linked phospholipase-C in FRTL-5 cells. However, the responses to ATP, its nonhydrolyzable derivatives, or ADP at the higher agonist concentrations, especially above 100 microM, were only partially inhibited by IAP, even though the IAP substrate was totally ADP ribosylated by the toxin. The responses to GTP in the whole concentration range tested were not influenced by IAP treatment. Thus, signals arising from the P2-receptor might be transduced to phospholipase-C by two different pathways, i.e. IAP-sensitive and insensitive ones, and result in the stimulation of I- efflux.
Okajima
F
F
Department of Physical Biochemistry, Gunma University, Maebashi, Japan.
Sho
K
K
Kondo
Y
Y
D000227:Adenine Nucleotides / Q000494:pharmacology; D000246:Adenosine Diphosphate Ribose / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism / Q000494:pharmacology; D002460:Cell Line; D003600:Cytosol / Q000378:metabolism; D006160:Guanosine Triphosphate / Q000494:pharmacology; D007295:Inositol Phosphates / Q000096:biosynthesis; D007454:Iodides / Q000378:metabolism*; D007457:Iodine Radioisotopes; D008970:Molecular Weight; D037342:Pertussis Toxin; D010716:Phosphatidylinositols / Q000378:metabolism*; D051381:Rats; D011983:Receptors, Purinergic / Q000187:drug effects / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013961:Thyroid Gland / Q000187:drug effects / Q000378:metabolism*; D013972:Thyrotropin / Q000494:pharmacology; D010566:Virulence Factors, Bordetella / Q000494:pharmacology*
D000227:Adenine Nucleotides; D007295:Inositol Phosphates; D007454:Iodides; D007457:Iodine Radioisotopes; D010716:Phosphatidylinositols; D011983:Receptors, Purinergic; D010566:Virulence Factors, Bordetella; D000246:Adenosine Diphosphate Ribose; D000001:Calcimycin; D006160:Guanosine Triphosphate; D000255:Adenosine Triphosphate; D013972:Thyrotropin; D037342:Pertussis Toxin; D013755:Tetradecanoylphorbol Acetate; D002118:Calcium